Skip main navigation

Review of AMR progress since 2013

Noah Fongwen presents two reviews of AMR progress since the WHO Call to Action in 2013.
NOAH FONGWEN: In this step, we’ll talk about two important reviews on AMR progress, the Lancet Commission and the Chatham House Review. In 2019, the medical journal the Lancet conducted a review of the successes and challenges of AMR programmes worldwide since the original AMR commission in 2013. Their findings can be summarised in the following three points. There has been increased awareness and political commitment leading to a high level meeting of the United Nations General Assembly in 2016. There’s been good progress on banning irrational drug combinations, commitments to ban colistin as a growth promoter in animals, improve hospital infection control, and better antimicrobial stewardship. However, there has been limited progress on funds mobilised and relaxed regulatory barriers to enable new antibiotic development.
In addition, the commission identified sustained funding for AMR and globally harmonised targets to monitor progress as priorities to move forward.
The Chatham House, an international think tank based in the United Kingdom, was funded by the Wellcome Trust to assess AMR progress against the recommendations of the O’Neil report. They found the following. They found that little progress has been made on the O’Neil report’s central and most expensive recommendations, transforming research and development incentives for antibiotics, vaccines, and diagnostics. They also found that there has been significant advances in reducing antibiotic use in agriculture, particularly in high income countries. But there is a long way to go in low-and-middle income countries. They found that there has been greater investment in awareness raising. But questions remain about its impact and effectiveness in changing behaviour.
Finally, they found out that proposals to restrict over-the-counter sales of antibiotics have foundered in the face of poor living conditions and access to health care in LMICs.

In 2014, the UK Prime Minister asked economist Jim O’Neill to analyse the global problem of rising drug resistance and propose concrete actions to tackle it internationally.

In this step, Dr. Fongwen walks us through two important reviews describing AMR progress since 2013, the Lancet Commission and the Chatham House Review, and progress with regards to the recommendations from the O’Neil Report.

This article is from the free online

Diagnostics for AMR: Building Back Better from the COVID-19 Pandemic

Created by
FutureLearn - Learning For Life

Our purpose is to transform access to education.

We offer a diverse selection of courses from leading universities and cultural institutions from around the world. These are delivered one step at a time, and are accessible on mobile, tablet and desktop, so you can fit learning around your life.

We believe learning should be an enjoyable, social experience, so our courses offer the opportunity to discuss what you’re learning with others as you go, helping you make fresh discoveries and form new ideas.
You can unlock new opportunities with unlimited access to hundreds of online short courses for a year by subscribing to our Unlimited package. Build your knowledge with top universities and organisations.

Learn more about how FutureLearn is transforming access to education